Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report

Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small c...

Descripción completa

Detalles Bibliográficos
Autores principales: XUE, XINYING, XUE, QINGLIANG, LIU, YUXIA, PAN, LEI, WANG, KAIFEI, ZHANG, LINA, WANG, NA, YANG, BING, WANG, JIANXIN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678659/
https://www.ncbi.nlm.nih.gov/pubmed/23761825
http://dx.doi.org/10.3892/ol.2013.1212
_version_ 1782272880334077952
author XUE, XINYING
XUE, QINGLIANG
LIU, YUXIA
PAN, LEI
WANG, KAIFEI
ZHANG, LINA
WANG, NA
YANG, BING
WANG, JIANXIN
author_facet XUE, XINYING
XUE, QINGLIANG
LIU, YUXIA
PAN, LEI
WANG, KAIFEI
ZHANG, LINA
WANG, NA
YANG, BING
WANG, JIANXIN
author_sort XUE, XINYING
collection PubMed
description Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD.
format Online
Article
Text
id pubmed-3678659
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-36786592013-06-11 Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report XUE, XINYING XUE, QINGLIANG LIU, YUXIA PAN, LEI WANG, KAIFEI ZHANG, LINA WANG, NA YANG, BING WANG, JIANXIN Oncol Lett Articles Gefitinib-induced interstitial lung disease (ILD) is a rare but lethal drug adverse event, which usually leads to the withdrawal of gefitinib and causes complications with anticancer treatment. In this study, gefitinib administration combined with prednisolone in a female with stage IIIb non-small cell lung cancer (NSCLC) produced a good outcome without inducing ILD. The results suggested that combined administration of gefitinib with glucocorticoids may be an efficient method to treat NSCLC while avoiding complications with ILD. D.A. Spandidos 2013-05 2013-02-27 /pmc/articles/PMC3678659/ /pubmed/23761825 http://dx.doi.org/10.3892/ol.2013.1212 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
XUE, XINYING
XUE, QINGLIANG
LIU, YUXIA
PAN, LEI
WANG, KAIFEI
ZHANG, LINA
WANG, NA
YANG, BING
WANG, JIANXIN
Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
title Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
title_full Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
title_fullStr Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
title_full_unstemmed Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
title_short Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
title_sort gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678659/
https://www.ncbi.nlm.nih.gov/pubmed/23761825
http://dx.doi.org/10.3892/ol.2013.1212
work_keys_str_mv AT xuexinying gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT xueqingliang gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT liuyuxia gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT panlei gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT wangkaifei gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT zhanglina gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT wangna gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT yangbing gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport
AT wangjianxin gefitinibincombinationwithprednisolonetoavoidinterstitiallungdiseaseduringnonsmallcelllungcancertreatmentacasereport

Ejemplares similares